# Is the duration of dual antiplatelet therapy (DAPT) excessive in post-angioplasty in chronic coronary syndrome? Data from the France-PCI registry (2014–2019)

A. Mezier, Pascal Motreff, J. M. Clerc, O. Bar, R. Deballon, T. Demicheli, T. Dechery, Géraud Souteyrand, A. Py, N. Lhoest, et al.

► To cite this version:

A. Mezier, Pascal Motreff, J. M. Clerc, O. Bar, R. Deballon, et al. Is the duration of dual antiplatelet therapy (DAPT) excessive in post-angioplasty in chronic coronary syndrome? Data from the France-PCI registry (2014–2019). Frontiers in Cardiovascular Medicine, 2023, 10, 10.3389/fcvm.2023.1106503. [https://doi.org/10.3389/fcvm.2023.1106503](https://doi.org/10.3389/fcvm.2023.1106503). [hal-05084579](https://HAL.inistre.fr/hal-05084579v1)

HAL Id: hal-05084579

https://hal.science/hal-05084579v1

Submitted on 26 May 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_2.png" /></figure>

Check for updates

OPEN ACCESS

EDITED BY

Veronique Regnault,
Institut National de la Santé et de la Recherche
Médicale (INSERM), France

REVIEWED BY

Alessandro Sticchi,
Humanitas Research Hospital, Italy
Tatsuhiko Otsuka,
Itabashi chuo medical center, Japan

*CORRESPONDENCE

A. Mezier

<figure><img src="image_3.png" /></figure>

amezier@chu-clermontferrand.fr

SPECIALTY SECTION

This article was submitted to Thrombosis, a
section of the journal Frontiers in
Cardiovascular Medicine

RECEIVED 23 November 2022

ACCEPTED 06 March 2023

PUBLISHED 24 March 2023

CITATION

Mezier A, Motreff P, Clerc JM, Bar O, Deballon R, Demicheli T, Dechery T, Souteyrand G, Py A, Lhoest N, Lhermusier T, Honton B, Gommeaux A, Jeanneteau J, Deharo P, Benamer H, Cayla G, Koning R, Pereira B, Collet JP and Rangé G (2023) Is the duration of dual antiplatelet therapy (DAPT) excessive in post-angioplasty in chronic coronary syndrome? Data from the France-PCI registry (2014–2019).

Front. Cardiovasc. Med. 10:1106503.

doi: 10.3389/fcvm.2023.1106503

COPYRIGHT

© 2023 Mezier, Motreff, Clerc, Bar, Deballon, Demicheli, Dechery, Souteyrand, Py, Lhoest, Lhermusier, Honton, Gommeaux, Jeanneteau, Deharo, Benamer, Cayla, Koning, Pereira, Collet and Rangé. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Is the duration of dual antiplatelet
therapy (DAPT) excessive in post-
angioplasty in chronic coronary
syndrome? Data from the France-
PCI registry (2014–2019)

A. Mezier¹*, P. Motreff¹, J. M. Clerc², O. Bar³, R. Deballon⁴,
T. Demicheli⁵, T. Dechery⁶, G. Souteyrand¹, A. Py⁷, N. Lhoest⁸,
T. Lhermusier⁹, B. Honton¹⁰, A. Gommeaux¹¹, J. Jeanneteau¹²,
P. Deharo¹³, H. Benamer¹⁴, G. Cayla¹⁵, R. Koning¹⁶, B. Pereira¹⁷,
J. P. Collet¹⁸ and G. Rangé⁵

¹Cardiology Department, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France,
²Cardiology Department, Centre Hospitalier Universitaire de Tours, Tours, France, ³Cardiology Department, Nouvelle Clinique Tourangelle, Saint-Cyr-sur-Loire, France, ⁴Cardiology Department, Clinique Oréliance, Orléans, France, ⁵Cardiology Department, Les Hôpitaux de Chartres, Chartres, France, ⁶Cardiology Department, Centre Hospitalier Jacques Cœur, Bourges, France, ⁷Cardiology Department, Clinique de l'Europe, Amiens, France, ⁸Cardiology Departemnt, Clinique Rhéna, Strasbourg, France, ⁹Cardiology Department, Centre Hospitalier Universitaire de Toulouse, Toulouse, France, ¹⁰Cardiology Department, Clinique Pasteur, Toulouse, France, ¹¹Cardiology Department, Hôpital Privé de Bois-Bernard, Bois-Bernard, France, ¹²Cardiology Department, Clinique Saint Joseph, Trelaze, France, ¹³Cardiology Department, Centre Hospitalier Universitaire de la Timone, Marseille, France, ¹⁴Cardiology Department, Institut Cardiovasculaire Paris Sud, Massy, France, ¹⁵Cardiology Department, Centre Hospitalier Universitaire de Nimes, Nimes, France, ¹⁶Cardiology Department, Clinique Saint Hilaire, Rouen, France, ¹⁷Clinical Research and Innovation Direction, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France, ¹⁸Cardiology Institute, Hôpital Pitié-Salpêtrière (Assistance Publique-Hôpitaux de Paris), Paris, France

**Background:** while the duration of dual antiplatelet therapy (DAPT) following coronary angioplasty for chronic coronary syndrome (CCS) recommended by the European Society of Cardiology has decreased over the last decade, little is known about the adherence to those guidelines in clinical practice in France.

**Aim:** To analyze the real duration of DAPT post coronary angioplasty in CCS, as well as the factors affecting this duration.

**Methods:** Between 2014 and 2019, 8.836 percutaneous coronary interventions for CCS from the France-PCI registry were evaluated, with 1 year follow up, after exclusion of patients receiving oral anticoagulants, procedures performed within one year of an acute coronary syndrome, and repeat angioplasty.

**Results:** Post-percutaneous coronary intervention (PCI) DAPT duration was > 12 months for 53.1% of patients treated for CCS; 30.5% had a DAPT between 7 and 12 months, and 16.4% a DAPT ≤ 6 months. Patients with L-DAPT (>12 months) were at higher ischemic risk [25.0% of DAPT score ≥2 vs. 18.8% DAPT score ≥2 in S&I-DAPT group (≤12 months)]. The most commonly used P2Y12 inhibitor was clopidogrel (82.2%). The prescription of ticagrelor increased over the period.

**Conclusions:** post-PCI DAPT duration in CCS was higher than international recommendations in the France PCI registry between 2014 and 2019. More than half of the angioplasty performed for CCS are followed by a DAPT > 12 months. Ischemic risk assessment influences the duration of DAPT. This risk is probably overestimated nowadays, leading to a prolongation of DAPT beyond the recommended durations, thus increasing the bleeding risk.

KEYWORDS

coronary angioplasty, chronic coronary syndrome, dual antiplatelet therapy, bleeding risk, ischemic risk
# Introduction

Coronary angioplasty is a routine treatment for chronic coronary syndrome (CCS) with ischemic lesion. Dual antiplatelet therapy (DAPT) is essential after coronary angioplasty to reduce thrombotic complications (mostly stent thrombosis). Advances in devices and techniques have increased the safety of coronary angioplasty by reducing those complications, with the development of the latest generations of drug eluting stent (DES) in particular (1, 2). These technological improvements have allowed a reduction in DAPT duration. In 2017, the DAPT duration recommended after coronary angioplasty for CCS was shortened to 6 months (3), from 6 to 12 months previously (4). The duration of DAPT should be adjusted for each patient, depending on individual bleeding and ischemic risk (3). Shorter DAPT duration is associated with increased risk of stent thrombosis (ST) and myocardial infarction (MI), while longer DAPT duration is at increased risk of bleeding. The recommended P2Y12 inhibitor in the context of CCS for post-coronary angioplasty is clopidogrel, in addition to aspirin (3–5).

We analyzed the real durations and component drugs of DAPT in post coronary angioplasty for CCS between 2014 and 2019, within the France PCI registry.

# Material and method

## France PCI registry

Data from the France PCI registry were used over a period of 6 years (2014–2019). France PCI is a national registry that aims to collect data on all coronary angiography and coronary angioplasty activities performed in France (6). The registry included 6 angioplasty sites in 2014, and 15 in 2019. 150 variables are systematically collected for each coronary angiography and/or coronary angioplasty procedure. This includes epidemiological, clinical, pre-hospital and procedural data, as well as a follow-up of the hospital stay and a follow-up at 1-year post-procedure. The pre-hospital and procedural data are collected by the operator and automatically extracted from the reports using software (Cardioreport®, Hémolia®), thus allowing an exhaustive collection of data >97% (7). The hospital follow-up data are collected from the patient’s medical file. The follow-up at 1 year [including collecting the effective duration and composition of the DAPT, ischemic event or bleeding event (classification BARC)] is done by phone contact with the patient. These data are then entered by dedicated on-site Clinical Research Associates or Clinical Study Technicians. Data of procedures from 2014 to 2019 and their 1-year follow-up were analyzed for this study.

## Inclusion and exclusion criteria

We focused on coronary angioplasty procedures performed in the context of CCS amongst all of the procedures included in the

France PCI registry. Procedures performed in the following contexts were considered as coronary angioplasties for CCS: planned angioplasty, stable angina, asymptomatic patient with positive ischemia test, preoperative cardiac and noncardiac surgery, pre Transcatheter Aortic Valve Implantation (TAVI), evaluation coronary angiography (left ventricular dysfunction, flow fractional reserve, optical coherence tomography etc.), and heart failure. Procedures performed in patients receiving oral anticoagulation before coronary angioplasty or within the year after PCI were excluded. Indeed, the co-administration of antiplatelet therapy and oral anticoagulant is subject to specific strategies (3, 8).

Procedures performed on patients with acute coronary syndrome (ACS) within the year before or after coronary angioplasty for CCS were deliberately excluded. The occurrence of ACS impacts the nature and duration of DAPT, leading to a bias at the time of data collection. In the event of iterative angioplasty for CCS over a 1-year period, only the last procedure was retained. Procedures in which the duration of DAPT was unknown were also excluded, as were patients who were not followed-up on or were deceased.

DAPT durations were considered short (S-DAPT) when less than or equal to 6 months, intermediate (I-DAPT) between 7 and 12 months inclusive, and long (L-DAPT) if they exceeded 12 months. The short and intermediate durations were pooled (S&I-DAPT) in order to be compared with the long durations.

The DAPT score was calculated from the France-PCI registry data according to the following criteria: 1 point each for MI at presentation (value = 0 for entire cohort because of inclusion criteria), prior MI or PCI, diabetes, stent diameter less than 3 mm, smoking, and paclitaxel-eluting stent (value = 0 for entire cohort because no Paclitaxel stents were implanted); 2 points each for low ejection fraction (<30%) and vein graft intervention; -1 point for age 65–74 years; and -2 points for age 75 years or older (9).

## Statistical analyses

Patient characteristics were described by numbers and percentages for categorical variables and by the mean and standard deviation or median and interquartile range, with respect to their statistical distribution, for variables of a quantitative nature. Comparisons between groups (≤ and >12 months) concerning quantitative variables considered the Student t test or the Mann-Whitney test when the conditions for application of the t test were not met. The hypothesis of normality was studied by the Shapiro-Wilk test, and that of equality of variances by the Fisher-Snedecor test. Chi-square and Fisher exact tests were used for comparisons of categorical variables between groups. As the unit of analysis was the angioplasty procedure (several measures for a same patient), random-effects models were performed as sensitivity analyses in order to take into account between and within patient variability (as random-effect). The results and the findings were not impacted. A sensitivity analysis was performed in order to
evaluate the representativeness of our sample comparing it with patients excluded from this analysis due to missing data or lack of information concerning lost to follow-up (Supplementary Material). All statistical analyses were performed with Stata software (version 15, StataCorp, College Station, United States) for a two-sided type I error at 5%.

## Results

Over the period 2014–2019, 95.909 procedures were collected in France PCI including 44,426 coronary angioplasty. Among them, 23.626 were coronary angioplasty for CCS. After applying exclusion criteria, we studied 8.836 angioplasty procedures for CCS (Figure 1). The characteristics of the population are detailed in Table 1. The mean age was 68.6 years (±10.4) with a predominantly male population (77.6%). The duration of DAPT of those 8.836 angioplasty procedures for CCS is shown in Figure 2. 4.146 (46.9%) were followed by S&I-DAPT, of which 1.446 (16.4%) ≤ 6 months and 2,700 (30.5%) between 7 and 12 months. 4.690 procedures (53.1%) were followed by a L-DAPT. The evolution of post-angioplasty DAPT durations is illustrated in Figure 3. DAPT durations are stable even though L-DAPT decreased from 56.6% in 2014 to 50.4% in 2019 it is still dominant compared to S&I-DAPT.

Patients receiving L-DAPT were significantly younger (68.3 vs. 68.9 years, *p* = 0.012) and more often men (79.1% vs. 75.9%, *p* < 0.001) (Table 1). Among the cardiovascular risk factors, diabetics were more represented in the L-DAPT group (34.3% vs. 29.1%, *p* < 0.001). The same goes for dyslipidemia (61.2% in the L-DAPT group vs. 56.6% in the S&I-DAPT group, *p* < 0.001), smoking (49.0% vs. 46.4%, *p* < 0.001), hypertension (63.7% vs.

61.7%, *p* = 0.043) or overweight (BMI ≥ 25 kg/m²) (70.2% vs. 66.7%, *p* = 0.005) with a mean BMI in the population of 27.6 (±4.71). There was no significant difference for coronary heredity.

Regarding cardiovascular history, only coronary angioplasty and prior MI (>1 year) were significantly more frequent in the L-DAPT group (42.2% vs. 35.2%, *p* < 0.001; and 16.1% vs. 13.8%, *p* = 0.003, respectively). L-DAPT was significantly more common in cases of severe left ventricular ejection fraction (LVEF < 30%) (4.1% vs. 2.7%, <0.001).

The distribution of DAPT score and the distribution of DAPT durations according to this score are shown in Figures 4.

Patients with a high DAPT score ≥ 2 at the time of the procedure (22.1%) significantly more often received prolonged treatment (25.0% L-DAPT vs. 18.8% S&I-DAPT, *p* < 0.001). The proportion of L-DAPT increased with the DAPT score, reaching more than 70% for the highest ischemic risk. Nevertheless, 75% of patients who received L-DAPT did not have a high DAPT score (≥2) at the time of the angioplasty procedure for CCS.

Durations of DAPT according to procedural data and hospital events and 1-year follow-up are detailed in Table 2. Multi-vessel patients are more frequently treated with L-DAPT (62.1% vs. 55.7%, *p* < 0.001), as well as patients with proximal lesions (62.3% vs. 57.1%, *p* < 0.001) or chronic total occlusion (CTO) (24.9% vs. 22.4%, *p* = 0.006). Long length (>20 mm) and small diameter (<3 mm) lesions were preferentially treated with L-DAPT. Regarding procedural data, there were significantly more multiple angioplasties in the L-DAPT group [18.8% number of dilated arteries >1 in the L-DAPT group vs. 15.7% (*p* < 0.001)], 40.6% number of dilated sites >1 in the L-DAPT group vs. 36.8% (*p* < 0.01), 43% number of stents implanted >1 in the L-DAPT group vs. 40% (*p* = 0.02). DAPT times were longer with stents of

<figure><img src="image_4.png" /></figure>
<table><caption>TABLE 1 DAPT durations according to population characteristics.</caption><thead><tr><th></th><th>S&I-DAPT (≤12 months)<br>n = 4146</th><th>L-DAPT (>12 months)<br>n = 4690</th><th>Total<br>n = 8836</th><th>p-value</th></tr></thead><tbody><tr><td colspan="5"><strong>Cardiovascular risk factors</strong></td></tr><tr><td>Age, mean (SD), year</td><td>68.9 (±10.4)</td><td>68.3 (±10.5)</td><td>68.6 (±10.4)</td><td>0.012</td></tr><tr><td>Male gender (%)</td><td>3,149 (75.9)</td><td>3,708 (79.1)</td><td>6,857 (77.6)</td><td>&lt;0.001</td></tr><tr><td>Overweight (BMI &gt;25) (%)</td><td>2,766 (66.7)</td><td>3,293 (70.2)</td><td>6,059 (68.6)</td><td>0.005</td></tr><tr><td>Hypertension (%)</td><td>2,558 (61.7)</td><td>2,988 (63.7)</td><td>5,546 (62.8)</td><td>0.043</td></tr><tr><td>Dyslipidaemia (%)</td><td>2,345 (56.6)</td><td>2,822 (61.2)</td><td>5,167 (58.5)</td><td>&lt;0.001</td></tr><tr><td>Smoking (%)</td><td>1,925 (46.4)</td><td>2,293 (49.0)</td><td>4,218 (47.7)</td><td>0.018</td></tr><tr><td>Active smoker (%)</td><td>567 (13.7)</td><td>776 (16.5)</td><td>1,343 (15.2)</td><td>&lt;0.001</td></tr><tr><td>Diabetes (%)</td><td>1,207 (29.1)</td><td>1,605 (34.3)</td><td>2,812 (31.9)</td><td>&lt;0.001</td></tr><tr><td>Non-insulin requiring (%)</td><td>997 (24.0)</td><td>1,227 (26.2)</td><td>2,224 (25.2)</td><td></td></tr><tr><td>Insulin-requiring (%)</td><td>210 (5.1)</td><td>378 (8.1)</td><td>588 (6.7)</td><td></td></tr><tr><td>Coronary heredity (%)</td><td>1,088 (26.2)</td><td>1,148 (24.5)</td><td>2,236 (25.3)</td><td>0.084</td></tr><tr><td colspan="5"><strong>Cardiovascular history</strong></td></tr><tr><td>Coronary angioplasty (%)</td><td>1,461 (35.2)</td><td>1,979 (42.2)</td><td>3,440 (38.9)</td><td>&lt;0.001</td></tr><tr><td>Myocardial infarction (&gt;1 year) (%)</td><td>570 (13.8)</td><td>752 (16.1)</td><td>1,322 (15.0)</td><td>0.003</td></tr><tr><td>Stroke (%)</td><td>130 (3.0)</td><td>132 (2.8)</td><td>262 (3.0)</td><td>0.373</td></tr><tr><td>Hemorrhage (%)</td><td>10 (0.2)</td><td>11 (0.2)</td><td>21 (0.2)</td><td>0.848</td></tr><tr><td>Peripheral vascular pathology (%)</td><td>538 (13.0)</td><td>676 (14.4)</td><td>1,214 (13.7)</td><td>0.054</td></tr><tr><td>Severe renal failure (%)</td><td>83 (2.0)</td><td>70 (1.5)</td><td>153 (1.7)</td><td>0.066</td></tr><tr><td>Severe left ventricular dysfunction (%)</td><td>105 (2.7)</td><td>182 (4.1%)</td><td>287 (3.4)</td><td>&lt;0.001</td></tr><tr><td>DAPT score, median (Quartile)</td><td>0 (–1; 1)</td><td>1 (0; 2)</td><td>0 (0; 1)</td><td>&lt;0.001</td></tr><tr><td>DAPT score ≥2 (%)</td><td>780 (18.8)</td><td>1,174 (25.0)</td><td>1,954 (22.1)</td><td>&lt;0.001</td></tr></tbody></table>

n, number of patients (%); SD, standard deviation; Severe left ventricular dysfunction = LVEF, left ventricular ejection fraction <30%; Severe renal failure = creatinine > 200 µmol/L.

<figure><img src="image_5.png" /><figcaption>FIGURE 2</figcaption></figure>

DAPT duration after coronary angioplasty for CCS in the France PCI registry (2014–2019) [n = number of procedures (%)]. CCS, chronic coronary syndrome; S-DAPT, short dual antiplatelet therapy; I-DAPT, short & intermediate dual antiplatelet therapy; L-DAPT, long dual antiplatelet therapy.

diameter < 3 mm (L-DAPT 49.9% vs. S&I-DAPT 47.2%, *p* = 0.012). 90.5% of angioplasties were performed with drug eluting stents (DES), with no significant difference (90.5 in S&I-DAPT group vs. 90.4% in L-DAPT group (*p* = 0.32).

Shorter DAPT times are observed in cases of severe bleeding (BARC ≥ 3) occurring intra-hospital or in the year after angioplasty for CCS.

Composition of DAPT: among the 8.836 procedures included procedures, 127 (0.14%) were followed by aspirin alone at discharge. For the 8.709 procedures followed by DAPT, aspirin was mostly combined with clopidogrel (82.2%), more rarely with ticagrelor (15%) or prasugrel (2.8%). In the S&I-DAPT group,

the anti-platelet therapy at 1 year post PCI was mostly aspirin monotherapy (91%), more rarely clopidogrel (7.4%), exceptionally ticagrelor or prasugrel (0.24%). There were no antiplatelet agents after 52 procedures at 1 year after the procedure (1.2%). The prescription of ticagrelor increased over the period (*p* < 0.001) (Table 3).

There was no significant difference in the proportion of patients still on DAPT at 1 year depending on the P2Y12 inhibitor used at discharge [54.1% with clopidogrel, 52.1% with ticagrelor or prasugrel (*p* = 0.16)].

Patients treated with ticagrelor or prasugrel were younger (mean age 64.6 (±10.2) vs. 69.4 (±10.3), *p* < 0.001), more often
<figure><img src="image_6.png" /><figcaption>FIGURE 3
Distribution of DAPT duration for CCS post angioplasty by year (%) (2014–2019). DAPT, dual antiplatelet therapy.</figcaption></figure>

<figure><img src="image_7.png" /></figure>

<table><thead><tr><th>DAPT score</th><th>-2</th><th>-1</th><th>0</th><th>1</th><th>2</th><th>3</th><th>≥4</th></tr></thead><tbody><tr><th>Number of procedures</th><td>539</td><td>1550</td><td>2414</td><td>2379</td><td>1379</td><td>471</td><td>104</td></tr></tbody></table>

<figure><img src="image_8.png" /></figure>

<table><caption>FIGURE 4
Distribution of the DAPT score (A). Distribution of dual antiplatelet therapy duration according to DAPT score (B). DAPT, dual antiplatelet therapy; S&I-DAPT, short and intermediate dual antiplatelet therapy (≤12 months); L-DAPT, long dual antiplatelet therapy (>12 months).</caption><thead><tr><th>DAPT score</th><th>-2</th><th>-1</th><th>0</th><th>1</th><th>2</th><th>3</th><th>≥4</th></tr></thead><tbody><tr><th>S&I-DAPT</th><td>267</td><td>815</td><td>1214</td><td>1070</td><td>580</td><td>170</td><td>30</td></tr><tr><th>L-DAPT</th><td>272</td><td>735</td><td>1200</td><td>1309</td><td>799</td><td>301</td><td>74</td></tr></tbody></table>

male (81.4% vs. 76.6%, *p* < 0.001), and overweight (71.7% vs. 67.9%, *p* = 0.012). They were also more likely to be current smokers or with a history of smoking (52.1% vs. 46.7%, *p* < 0.001). They had more history of MI (20.0% vs. 13.8%, *p* < 0.001) and coronary angioplasty (44.8% vs. 37.6%, *p* < 0.001). Patients receiving clopidogrel were more likely to have severe renal failure (1.9% vs. 1.0%, *p* = 0.018), and significantly more hypertension (63.9% vs. 57.2%, *p* < 0.001). Patients treated with ticagrelor or prasugrel were associated with higher DAPT score [DAPT score ≥ 2 in 31.5% of cases vs. 20.2% of cases for clopidogrel (*p* < 0.001)] (Supplementary Material).

In terms of procedural data, multi-vessels coronary disease and isolated left main coronary artery stenosis were not significantly more often treated with ticagrelor or prasugrel than with clopidogrel (60.1% vs. 58.9% and 0.8% vs. 0.6%, *p* = 0.43). The same applies to the treatment of proximal lesions (61.6% vs. 59.5%, *p* = 0.13), dilated arteries >1 (18.4% vs. 17.3%, *p* = 0.27), or presence of CTO (23.0% vs. 23.1%, *p* = 0.93). From the procedural data, only multiple stenting (number of stents implanted >1) was more often associated with the use of ticagrelor or prasugrel (45.0% vs. 40.9%, *p* < 0.01).
<table><caption>TABLE 2 DAPT durations according to procedural data, in-hospital events and 1-year follow-up.</caption><thead><tr><th></th><th>S&I-DAPT (≤12 months)<br>n = 4146</th><th>L-DAPT (>12 months)<br>n = 4690</th><th>Total<br>n = 8836</th><th>p-value</th></tr></thead><tbody><tr><td><strong>Lesion characteristics</strong></td><td></td><td></td><td></td><td></td></tr><tr><td>Number of vessel(s) affected (%)</td><td></td><td></td><td></td><td>&lt;0.001</td></tr><tr><td>Monotruncular</td><td>1,815 (43.8)</td><td>1,747 (37.2)</td><td>3,562 (40.3)</td><td></td></tr><tr><td>Pluritruncal</td><td>2,309 (55.7)</td><td>2,911 (62.1)</td><td>5,220 (59.1)</td><td></td></tr><tr><td>Isolated left main</td><td>22 (0.5)</td><td>32 (0.7)</td><td>54 (0.6)</td><td></td></tr><tr><td>Presence of proximal lesion (%)</td><td>2,367 (57.1)</td><td>2,922 (62.3)</td><td>5,289 (59.9)</td><td>&lt;0.001</td></tr><tr><td>Presence of CTO (%)</td><td>928 (22.4)</td><td>1,166 (24.9)</td><td>2,094 (23.7)</td><td>0.006</td></tr><tr><td>Presence of CABG (%)</td><td>276 (6.7)</td><td>397 (8.5)</td><td>673 (7.6)</td><td>0.001</td></tr><tr><td>Artery diameter at lesion &lt;3 mm (%)</td><td>2,590 (62.5)</td><td>3,157 (67.3)</td><td>5,747 (65.0)</td><td>&lt;0.001</td></tr><tr><td>Lesion length &gt;20 mm (%)</td><td>1,767 (42.6)</td><td>2,182 (46.5)</td><td>3,949 (44.7)</td><td>&lt;0.001</td></tr><tr><td><strong>Characteristics of angioplasty</strong></td><td></td><td></td><td></td><td></td></tr><tr><td>Number of dilated arteries &gt;1 (%)</td><td>649 (15.7)</td><td>881 (18.8)</td><td>1,530 (17.3)</td><td>&lt;0.001</td></tr><tr><td>Number of dilated sites &gt;1 (%)</td><td>1,526 (36.8)</td><td>1,902 (40.6)</td><td>3,428 (38.8)</td><td>&lt;0.001</td></tr><tr><td>Number of stents implanted &gt;1 (%)</td><td>1,649 (39.8)</td><td>1,997 (42.6)</td><td>3,646 (41.3)</td><td>0.007</td></tr><tr><td>Stent diameter &lt;3 mm (%)</td><td>1,959 (47.2)</td><td>2,341 (49.9)</td><td>4,300 (48.7)</td><td>0.012</td></tr><tr><td>Type of stent(%)</td><td></td><td></td><td></td><td>0.32</td></tr><tr><td>Drug eluting stent (DES)</td><td>3,753 (90.5)</td><td>4,240 (90.4)</td><td>7,993 (90.5)</td><td></td></tr><tr><td>Bare metal stent (BMS)</td><td>134 (3.2)</td><td>126 (2.6)</td><td>260 (2.9)</td><td></td></tr><tr><td>Drug-coated balloon (DCB)</td><td>89 (2.1)</td><td>116 (2.4)</td><td>205 (2.3)</td><td></td></tr><tr><td>Bioreorbable vascular scaffold (BVS)</td><td>19 (0.5)</td><td>22 (0.5)</td><td>41 (0.4)</td><td></td></tr><tr><td>Balloon angioplasty alone.</td><td>321 (7.7)</td><td>398 (8.4)</td><td>719 (8.1)</td><td></td></tr><tr><td><strong>In-hospital events</strong></td><td></td><td></td><td></td><td></td></tr><tr><td>Severe bleeding (BARC ≥ 3) (%)</td><td>16 (0.39)</td><td>6 (0.13)</td><td>22 (0.25)</td><td>0.015</td></tr><tr><td>Stroke (%)</td><td>3 (0.07)</td><td>2 (0.04)</td><td>5 (0.06)</td><td>0.76</td></tr><tr><td>Ischemic (%)</td><td>2 (0.05)</td><td>2 (0.04)</td><td>4 (0.05)</td><td></td></tr><tr><td>Hemorrhage (%)</td><td>1 (0.02)</td><td>0</td><td>1 (0.01)</td><td></td></tr><tr><td><strong>Events at 1 year</strong></td><td></td><td></td><td></td><td></td></tr><tr><td>Severe bleeding (BARC ≥ 3) (%)</td><td>96 (2.3)</td><td>23 (0.5)</td><td>119 (1.3)</td><td>&lt;0.001</td></tr><tr><td>Stroke (%)</td><td>14 (0.34)</td><td>16 (0.34)</td><td>30 (0.3)</td><td>0.87</td></tr><tr><td>Ischemic (%)</td><td>11 (0.27)</td><td>12 (0.26)</td><td>23 (0.26)</td><td></td></tr><tr><td>Hemorrhage (%)</td><td>2 (0.05)</td><td>1 (0.02)</td><td>3 (0.03)</td><td></td></tr><tr><td>Unspecified (%)</td><td>1 (0.02)</td><td>3 (0.06)</td><td>4 (0.05)</td><td></td></tr></tbody></table>

CTO, chronic total occlusion; CABG, coronary artery bypass graft; BARC, Bleeding Academic Research Consortium.

<table><caption>TABLE 3 Evolution of P2Y12 inhibitors used in post angioplasty for CCS.</caption><thead><tr><th></th><th>2014</th><th>2015</th><th>2016</th><th>2017</th><th>2018</th><th>2019</th><th></th></tr></thead><tbody><tr><td>Clopidogrel</td><td>756 (81.9)</td><td>812 (83.1)</td><td>1,107 (85.6)</td><td>1,384 (79.0)</td><td>1,509 (83.5)</td><td>1,591 (81.3)</td><td>7,159 (82.2)</td></tr><tr><td>Ticagrelor/Prasugrel</td><td>167 (18.1)</td><td>165 (16.9)</td><td>187 (14.4)</td><td>367 (21.0)</td><td>299 (16.5)</td><td>365 (18.7)</td><td>1,550 (17.8)</td></tr><tr><td>Ticagrelor</td><td>112 (12.1)</td><td>120 (12.3)</td><td>144 (11.1)</td><td>323 (18.4)</td><td>268 (14.8)</td><td>343 (17.5)</td><td>1,310 (15.0)</td></tr><tr><td>Prasugrel</td><td>55 (6.0)</td><td>45 (4.6)</td><td>43 (3.3)</td><td>44 (2.5)</td><td>31 (1.7)</td><td>22 (1.2)</td><td>240 (2.8)</td></tr><tr><td></td><td>923</td><td>977</td><td>1294</td><td>1751</td><td>1808</td><td>1956</td><td>8709</td></tr></tbody></table>

Discussion

In this homogeneous population managed by angioplasty for CCS between 2014 and 2019, more than half of the procedures were followed by a duration of DAPT > 12 months (53.1%), higher than the duration recommended by European guidelines (3–5). No major changes in the duration of DAPT were found during this period, although the proportion of L-DAPT decreased slightly from 56.6% in 2014 to 50.4% in 2019 while S-DAPT rose from 13.2% in 2014 to 18.4% in 2019.

The recommendations are based on studies confirming the progress observed with the latest generation of DES and the

substantial decrease in stent thrombosis rate (2, 5). The recommendations published by the ESC in 2017 which proposed to shorten the duration of DAPT post PCI for CCS to 6 months (3), had no impact on the French practices observed in 2018–2019. Moreover, 17.8% of patients are treated with ticagrelor and prasugrel despite the lack of studies demonstrating the superiority of these molecules in this indication (10). In the ESC guidelines their use may be considered (class IIb) in situations with high risk of stent thrombosis based on procedural data (5). Most notably, there has been an increase in the use of ticagrelor from 12.1% in 2014 to 17.5% in 2019. In the national Swedish Coronary Angiography and Angioplasty Registry (SCAAR), the use of ticagrelor post PCI for
CCS is also observed in almost a third of cases (period 2013–2020, Swedeheart Annual Report 2020 – SCAAR).

In the procedural data concerning our cohort, only multiple stenting (number of stents implanted >1) was significantly associated with the use of ticagrelor or prasugrel. Furthermore, the ticagrelor/prasugrel subgroup had more clinical ischemic risk factors (male gender, smoking, previous MI and/or angioplasty). Similarly, they had a significantly more frequent DAPT score >2 (31.5% vs. 20.2%; *p* < 0.001). Thus, in practice, the preference for ticagrelor or prasugrel in post angioplasty for CCS would be guided more by patient profile than by procedural data.

There are very few data on actual durations of post-coronary angioplasty DAPT in the real world. Only a few observational studies have looked at DAPT times and their clinical impact, but these data are prior to 2014, with different techniques and materials, or concern post-MI (11–13). The few observations made with similar but underpowered cohort also show a significant proportion of long DAPT, often beyond the recommended durations (14). These results confirm the poor adherence to clinical practice recommendations regarding the duration and composition of DAPT after coronary angioplasty in CCS. Adherence to the guidelines has been shown to correlate with improved prognosis (5, 15). If we extrapolate the results of studies dedicated to the clinical impact of short DAPT on the occurrence of bleeding events without increasing the ischemic risk (16, 17), we can imagine the medico-economic consequences of better compliance with the recommendations (cost of treatment, hemorrhagic morbidity and mortality, etc.).

Through this study, we can measure the interest of having an exhaustive and reliable registry, which would allow us to analyze medical practices in real life, in a field such as post-angioplasty DAPT which is constantly evolving due to the progress of equipment and new knowledge. The reactivity of the analysis of these data reinforces the monitoring of the evolution of interventional cardiology practices and measuring the impact of corrective measures.

The duration of DAPT should be individually determined according to the ischemic and hemorrhagic risk. There are clinical and procedural elements that may prolong DAPT even in the context of CCS (3, 9). However, in our study we found that the actual duration of post-angioplasty for CCS was significantly longer than the recommended duration for more than half of the procedures, which seems to be excessive in relation to the usual proportion of patients who can be considered at high ischemic risk.

We can imagine that old habits and the fear of ischemic complications lead the operators to extend the duration of DAPT, or even to use more powerful drugs like ticagrelor or prasugrel. The perception of the hemorrhagic risk is possibly underestimated by the interventional cardiologist who is less directly involved in the clinical consequences than in the case of thrombotic complications (intracerebral hemorrhages, digestive hemorrhages). Moreover, we can raised the hypothesis of a delay between the publication of the recommendations and their execution. The late discontinuation of one of the two PAAs can also be explained by insufficient dissemination of information to the various health care actors [non-interventional cardiologist, general practitioner (GP)]. In the absence of all the factors

required to estimate the ischemic risk and in the absence of bleeding during the period of recommended DAPT, the referring cardiologist or the GP will tend to maintain DAPT beyond the recommended durations in fear of an ischemic event, and in particular an ST, will occur after the cessation of DAPT. The duration of DAPT may not be sufficiently explicit on the discharge prescription. Moreover, the GP is reluctant to stop such treatment without clear instructions from cardiologist. The decline in medical demography has led to a gap in follow-up consultations, which may also explain a delay in the adjustment of treatments and particularly of DAPT.

The DAPT score was originally designed to stratify the ischemic and hemorrhagic risk of each patient in order to adapt the duration of DAPT in patients who had completed 12 months of DAPT without having a major bleeding or ischemic event and who were not on chronic oral anticoagulation. For this study, we calculated it with pre- and in-hospital data. The relevance of this score has been questioned in the assessment of bleeding risk (18) for which it was not recommended. On the other hand, the DAPT score allows the identification of patients at high ischemic risk (19), as recommended in the 2017 ESC recommendations (3), although the predictive value of this score has not been found in large registries (20, 21). In our study, we found that there are more patients with a high DAPT score (≥2) in the L-DAPT group. The higher the DAPT score, the more patients received L-DAPT (Figure 4B). Although the DAPT score was not reported a priori and is not widely used in routine practice, its criteria influenced DAPT durations. Although in our study there was a relationship between prolonged DAPT duration and DAPT score, it should be noted that 75% of patients treated with DAPT >12 months did not have a high DAPT score (22). The median DAPT score is lower in our series than in the study by Yeh et al. where the median was 2 (9), highlighting a moderate ischemic risk, due to exclusion of ACS, supporting the statement of an unjustified extension of DAPT. Systematic calculation and scrupulous respect of the DAPT score could be a tool to limit prolonged DAPT and reserve it only for subjects at higher ischemic risk (22.1% of DAPT score >2 in our series, or a rate 2.4 times lower than that of L-DAPT observed).

This study is observational, based on a registry. Although it allows us to analyze data from a large number of patients and procedures, it represents a sample of 15 French centers. Thus, a “center effect” cannot be ruled out in our analysis, even if we have not observed any major disparity in practices between the different centers (annual reports; https://www.francepci.com). It is not possible through a registry to establish a causal link between post-procedural events and the duration or composition of DAPT. The rare ischemic events were excluded in order not to include ACS. Paradoxically, hemorrhagic events are more frequent in short treatment durations, and the occurrence of these hemorrhagic events probably led to the reduction of antithrombotic treatments considered responsible or at least a co-factor. Indeed DAPT is often stopped for monotherapy when bleeding event occurs with DAPT.

The aim of the study is to document practices in relation to the recommendations and not to discuss the clinical relevance of prescriptions, which is based on prospective randomized trials.
## Limitations

In order to study a homogeneous population, only managed for CCS, we imposed exclusion criteria likely to rule out profiles at high risk of bleeding (no co-prescription of anticoagulants often administered for atrial fibrillation in a more fragile and elderly population), or ischemic (ACS in the year surrounding inclusion or new angioplasty in the year following the procedure). These criteria allowed us to avoid many biases at the cost of selecting a population free of post-angioplasty ischemic complications. Thus, the ischemic risk is reduced in this selected population (exclusion of any ACS). This constitutes a bias in the selection of patients, as well as the exclusion of patients who died in the year following the procedure, but this is necessary, as our main aim was to analyse the effective duration of post-angioplasty DAPT, data collected one year after the procedure, this data is missing for patients who died. The risk of bleeding also needs to be reconsidered because of the exclusion of patients on anticoagulants. Missing or incomplete data at 1-year follow-up is a significant limitation of the study. The rate of prolonged prescription of DAPT is not transposable to the general population.

## Conclusions

The duration of DAPT after angioplasty for CCS in France is longer than that recommended by international guidelines, with in particular a duration of DAPT > 12 months for more than half of the patients undergoing post-angioplasty for CCS. Approximately one fifth of patients are treated with ticagrelor or prasugrel instead of clopidogrel. These results and the data in the literature on the ischemic/hemorrhagic risk related to the duration of DAPT should encourage the alignment of practices with the guidelines.

## Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

## Ethics statement

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. The patients/participants provided their written informed consent to participate in this study.

## Author contributions

MA: Conception and design of the work. Acquisition, analysis and interpretation of data. Review, draft preparation and final approval of the manuscript. MP: Design of the work, acquisition,

analysis, or interpretation of data. Critical review, draft preparation and final approval of the manuscript. CJM: Acquisition of data. Critical review, draft preparation and final approval of the manuscript. BO: Acquisition of data. Critical review, draft preparation and final approval of the manuscript. DR: Acquisition of data. Critical review, draft preparation and final approval of the manuscript. DT: Acquisition of data. Critical review, draft preparation and final approval of the manuscript. SG: Acquisition of data. Critical review, draft preparation and final approval of the manuscript. PA: Acquisition of data. Critical review, draft preparation and final approval of the manuscript. LN: Acquisition of data. Critical review, draft preparation and final approval of the manuscript. LT: Acquisition of data. Critical review, draft preparation and final approval of the manuscript. HB: Acquisition of data. Critical review, draft preparation and final approval of the manuscript. GA: Acquisition of data. Critical review, draft preparation and final approval of the manuscript. JJ: Acquisition of data. Critical review, draft preparation and final approval of the manuscript. DP: Acquisition of data. Critical review, draft preparation and final approval of the manuscript. BH: Acquisition of data. Critical review, draft preparation and final approval of the manuscript. CG: Acquisition of data. Critical review, draft preparation and final approval of the manuscript. KR: Acquisition of data. Critical review, draft preparation and final approval of the manuscript. PB: Statistical analysis. Critical review, draft preparation and final approval of the manuscript. RG: Acquisition of data. Critical review, draft preparation and final approval of the manuscript. All authors contributed to the article and approved the submitted version.

## Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2023.1106503/full#supplementary-material.
References

1. Machado C, Raposo L, Dores H, Leal S, Campante Teles R, de Araújo Gonçalves P, et al. Second-generation versus first-generation drug-eluting stents for the treatment of patients with acute coronary syndromes and obstructive coronary artery disease. *Coron Artery Dis.* (2014) 25(3):208-14. doi: 10.1097/MCA.0000000000000078

2. Collet JP, Silvain J, Kerneis M, Cuisset T, Meneveau N, Boueri Z, et al. Clinical outcome of first- vs second-generation DES according to DAPT duration: results of ARCTIC-generation. *Clin Cardiol.* (2016) 39(4):192-200. doi: 10.1002/clc.22512

3. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European society of cardiology (ESC) and of the European association for cardio-thoracic surgery (EACTS). *Eur Heart J.* (2018) 39(3):213-60. doi: 10.1093/eurheartj/ehx419

4. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European society of cardiology. *Eur Heart J.* (2013) 34(38):2949-3003. doi: 10.1093/eurheartj/eht296

5. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J.* (2020) 41(3):407-77. doi: 10.1093/eurheartj/ehz425

6. Rangé G, Chassaing S, Marcollet P, Saint-Étienne C, Dequenne P, Goralski M, et al. The CRAC cohort model: a computerized low cost registry of interventional cardiology with daily update and long-term follow-up. *Rev Epidemiol Sante Publique.* (2018) 66(3):209-16. doi: 10.1016/j.respe.2018.01.135

7. Dawson LP, Biswas S, Lefkovits J, Stub D, Burchill L, Evans SM, et al. Characteristics and quality of national cardiac registries: a systematic review. *Circ Cardiovasc Qual Outcomes.* (2021) 14(9):e007963. doi: 10.1161/CIRCOUTCOMES.121.007963

8. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European society of cardiology (ESC) developed with the special contribution of the European heart rhythm association (EHRA) of the ESC. *Eur Heart J.* (2021) 42(5):373-498. doi: 10.1093/eurheartj/eha612

9. Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. *JAMA.* (2016) 315(16):1735-49. doi: 10.1001/jama.2016.3775

10. Silvain J, Lattuca B, Beygui F, Rangé G, Motovska Z, Dillinger JG, et al. Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial. *Lancet.* (2020) 396 (10264):1737-44. doi: 10.1016/S0140-6736(20)32236-4

11. So HS, So MG, Kang SI, Park JJ, Lee JH, Kim U, et al. Long-Term safety and efficacy of extended dual antiplatelet therapy after drug-eluting stent implantation in real-world practice. *Circ J.* (2020) 84(12):2175-84. doi: 10.1253/circj.CJ-20-0668

12. Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. *Lancet.* (2013) 382(9906):1714-22. doi: 10.1016/S0140-6736(13)61720-1

13. Degli Esposti L, Perrone V, Veronesi C, Buda S, Rossini R, a LHUs Group. Long-Term use of antiplatelet therapy in real-world patients with acute myocardial infarction: insights from the PIPER study. *TH Open.* (2018) 2(4):e437-444. doi: 10.1055/s-0038-1676529

14. Lee OH, Kim BK, Hong SJ, Kim S, Ahn CM, Shin DH, et al. Determinants and clinical outcomes of extended dual antiplatelet therapy over 3 years after drug-eluting stent implantation: a retrospective analysis. *Yonsei Med J.* (2020) 61(7):597-605. doi: 10.3349/ymj.2020.61.7.597

15. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European society of cardiology (ESC). *Eur Heart J.* (2016) 37 (3):267-315. doi: 10.1093/eurheartj/ehv320

16. Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the efficacy of Xience/promus versus cypher to reduce late loss after stenting (EXCELLENT) randomized, multicenter study. *Circulation.* (2012) 125(3):505-13. doi: 10.1161/CIRCULATIONAHA.111.059022

17. Schulz-Schüpke S, Byrne RA, Ten Berg JM, Neumann FJ, Han Y, Adriaenssens T, et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. *Eur Heart J.* (2015) 36 (20):1252-63. doi: 10.1093/eurheartj/ehu523

18. Chichareon P, Modolo R, Kawashima H, Takahashi K, Kogame N, Chang CC, et al. DAPT Score and the impact of ticagrelor monotherapy during the second year after PCI. *JACC Cardiovasc Interv.* (2020) 13(5):634-46. doi: 10.1016/j.jcin.2019.12.018

19. Mihatov N, Secemsky EA, Kereiakes DJ, Steg G, Serruys PW, Chichareon P, et al. Utility of the dual antiplatelet therapy score to guide antiplatelet therapy: a systematic review and meta-analysis. *Catheter Cardiovasc Interv.* (2021) 97(4):569-78. doi: 10.1002/ccd.29352

20. Ueda P, Jernberg T, James S, Alfredsson J, Erlinge D, Omerovic E, et al. External validation of the DAPT score in a nationwide population. *J Am Coll Cardiol.* (2018) 72 (10):1069-78. doi: 10.1016/j.jacc.2018.06.023

21. Witberg G, Zusman O, Bental T, Plakht I, Gabbay H, Gerber Y, et al. Validation of the DAPT score in real-world patients undergoing coronary stent implantation. *Int J Cardiol.* (2020) 300:99-105. doi: 10.1016/j.ijcard.2019.08.044

22. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. *Eur Heart J.* (2019) 40(2):87-165. Erratum in: *Eur Heart J.* (2019);40(37):3096. doi: 10.1093/eurheartj/ehy394